POST-TEST

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which clinical disease stages were eligible for enrollment in the Phase III ALINA trial of adjuvant alectinib versus platinum-based chemotherapy for patients with resected localized non-small cell lung cancer (NSCLC) with an ALK rearrangement?**
   a. Stage IB to II
   b. Stage II to IIIB
   c. Stage II only
   d. Stage IB to IIIA

2. **Which of the following adverse events was most associated with adjuvant alectinib therapy for patients with localized NSCLC with an ALK rearrangement?**
   a. Neutropenia
   b. Nausea
   c. Constipation
   d. Dysgeusia

3. **In the intent-to-treat population, what efficacy finding was reported in the Phase III ALINA study?**
   a. Inferior disease-free survival (DFS) outcomes with alectinib versus chemotherapy
   b. No significant difference in DFS outcomes with alectinib versus chemotherapy
   c. A superior and significant improvement in DFS with alectinib versus chemotherapy

4. **In the intent-to-treat population of the Phase III ALINA study, what was reported with regard to CNS DFS outcomes?**
   a. No meaningful reduction in the rate of CNS metastases in patients that received alectinib versus chemotherapy
   b. A significant reduction in the rate of CNS metastases in patients that received alectinib versus chemotherapy
   c. There was no reporting of CNS DFS outcomes in the ALINA trial

5. **The Phase II NAUTIKA1 trial is evaluating alectinib in which clinical setting for patients with localized, ALK-rearranged NSCLC?**
   a. In combination with immunotherapy in the neoadjuvant setting
   b. As monotherapy in the neoadjuvant setting
   c. In combination with durvalumab after chemoradiotherapy